ChromaDex Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $20.32M Beat $19.19M Estimate
Portfolio Pulse from Benzinga Newsdesk
ChromaDex (NASDAQ:CDXC) reported Q2 earnings per share of $(0.03), beating the analyst consensus estimate of $(0.04) by 25%. This is a 66.67% increase over losses from the same period last year. The company also reported quarterly sales of $20.32 million, beating the analyst consensus estimate of $19.19 million by 5.90%. This is a 21.46% increase over sales from the same period last year.
August 09, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex's Q2 earnings and sales beat estimates, showing significant YoY growth. This could positively impact the stock in the short term.
ChromaDex's Q2 earnings and sales exceeded analyst estimates and showed significant year-over-year growth. This positive financial performance could increase investor confidence and demand for the stock, potentially driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100